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INTRODUCTION
Pregnant women are vulnerable to malaria
infection. Pregnancy-associated malaria can causes
adverse pregnancy outcomes including abortion,
preterm birth, low birth weight, congenital malaria,
intrauterine growth retardation (IUGR), anemia
and metabolic disorders that increase the risk of
disease in later stages of child development.1
Numerous studies have reported on the pre-
valence of peripheral parasitaemia and placental
parasitaemia in the area stable endemic malaria
transmission in Africa. The median prevalence of
maternal malaria infection (defined as an infection
of peripheral or placenta) for all gravid was 27.8%.
The highest risk of maternal malaria infection
occurred during the second trimester of pregnancy
while at the early postpartum period study showed
inconsistent.2
Abstract
Objective: To determine the effect of artesunate on peripheral
parasitaemia in pregnant women with Plasmodium falciparum
infection.
Methods: Pregnant women in second and third trimester with Plas-
modium falciparum infection and their newborns were included in
cohort prospective study in Sorong West Papua from September
2015 to February 2016. All pregnant women received 200 mg orally
artesunate monotherapy for 7 days. Their newborns examined for
weight at delivery and parasitaemia in placenta and cord blood.
Parasitaemia diagnosis by Rapid Diagnostic Test and blood smear
microscopy.
Results: After artesunatemonotherapy, 82.5% (33/40) malaria-
infected pregnant women had negative parasitaemia (p=0.000)
although 17.5% (7/40) of the pregnant women had positive para-
sitaemia. Parasitaemia also found in 10% (4/40) of placenta and
7.5% (3/40) of umbilical cord from newborns of malaria-infected
pregnant women treated with artesunate. 70% (28/40) of the
newborns in this study had normal weight.
Conclusion: Artesunate reduces peripheral parasitaemia in the
second and third trimester of pregnancy, and is associated with
normal birth weight.
[Indones J Obstet Gynecol 2017; 5-3: 135-138]
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Abstrak
Tujuan: Untuk mengetahui pengaruh artesunat pada ibu hamil
yang terinfeksi Plasmodium falciparum dengan kejadian para-sitemia perifer.
Metode: Penelitian kohort prospektif dilakukan pada perempuanhamil trimester kedua dan ketiga dengan infeksi Plasmodium falci-
parum dan bayinya di Sorong Papua Barat dari September 2015 sam-
pai Februari 2016. Semua perempuan hamil memperoleh mono terapiartesunat 200 mg per oral selama 7 hari. Pada bayi dilakukan pe-
meriksaan berat badan saat persalinan dan parasitemia padaplasenta dan darah tali pusat. Diagnosis parasitemia dengan Rapid
Diagnostic Test dan pemeriksaan apusan darah mikroskopik.
Hasil: Setelah terapi artesunat, ditemukan parasitemia negatif
pada 82,5% (33/40) perempuan hamil yang terinfeksi malaria (p =
0,000) meskipun 17,5% (7/40) di antaranya parasitemia positif.Parasitemia juga ditemukan 10% (4/40) pada plasenta dan 7,5%
(3/40) pada tali pusat bayi yang lahir dari perempuan denganinfeksi Plasmodium falciparum yang mendapatkan pengobatan
artesunat. 70% (28/40) dari bayi yang lahir dalam penelitian
memiliki berat badan normal.
Kesimpulan: Artesunat menurunkan kejadian parasitemia perifer
pada perempuan hamil trimester kedua dan ketiga. Bayi yang lahirdari perempuan hamil yang mendapatkan terapi artesunat memiliki
berat badan normal.
[Maj Obstet Ginekol Indones 2017; 5-3: 135-138]
Kata kunci: artesunat, berat bayi lahir rendah, parasitemia perifer
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Plasmodium falciparum is the most common
Plasmodium species in Indonesia.3 A study in
Timika- Papua, an area of multidrug-resistant to P.
vivax and P. falciparum, show both species are
associated with substantial morbidity.4 P. vivax
and P. falciparum have been previously reported
to be chloroquine resistant in Papua.5
Any attempt for malaria prevention in Indonesia
is controlled by Annual Parasite Incidence (API)
since 2007. This policy requires that every case of
malaria infection has to be confirmed with blood
smear microscopy and treated with artemisin-
based combination therapy (ACT).6 ACT signifi-
cantly reduced the vertical transmission risk
of malaria in Papua.7 Other studies demonstrated
that a single dose of artesunate monotherapy was
effective and had no adverse effect in the second
and third trimester of pregnancy.8
This study is aimed to determine the effect of
artesunate therapy in peripheral parasitaemia on
second and third trimester of pregnancy with
P. falciparum infection and their newborns after
treatment.
METHODS
This prospective cohort study was conducted in
health facilities in Sorong, West Papua from Sep-
tember 2015 to February 2016. Pregnant women
infected with falciparum malaria in the second and
third trimester and their newborns from Waisai
General Hospital, Timika General Hospital, Sele Be
Solu Hospital and Makbon Community Health
Center were enrolled in this study. Parasitaemia
in capillary blood from pregnant women and
placenta and cord blood from newborns were
diagnosed by blood smear microscopy and a Rapid
Diagnostic Test (RDT). Pregnant women were
administered with artesunate monotherapy 200
mg (4 mg/kg) per oral once daily for 7 days.
Newborns weight was measured at delivery; birth
weight <2500 g defined as low birth weight.
Pregnant women with complicated malaria, have
taken other anti-malarial drugs prior to data
collection, and unwilling to join the study were
excluded. McNemar test was used to analyze the
effect of artesunate therapy on peripheral
parasitaemia. The study protocol was approved by
the Health Research Ethics Committee of Faculty
of Medicine, Hasanuddin University.
RESULTS
This study involved 40 pregnant women with fal-
ciparum malaria. After being administered with
artesunate therapy, 82.5% (33/40) malaria-
infected pregnant women had negative parasitae-
mia although 17.5% (7/40) of these women had
positive parasitaemia (17.5%). These differences
were statistically significant (p<0.001). The results
are shown in Table 1.
Table 1. Peripheral Parasitaemia on Pregnant Women







RDT 33 (82.5) 7 (17.5) < 0.001
Microscopic 33 (82.5) 7 (17.5) < 0.001
*McNemar test
Parasitaemia positive was found 10% (4/40)
positive in placenta and 7.5% (3/40) in umbilical
cord from newborns of malaria-infected women
treated with artesunate (Table 2). Seventy percent
of the newborns in this study born had normal
birthweight (Table 3).
Table 2. Parasitaemia on Placenta and Umbilical Cord
Parasitaemia (n=40) Negative n% Positive n%
Placenta 
RDT 36 (90) 4 (10)
Microscopic 36 (90) 4 (10)
Umbilical cord
RDT 37 (92.5) 3 (7.5)
Microscopic 37 (92.5) 3 (7.5)






The study is aimed to determine the effect of
artesunate therapy in peripheral parasitaemia on
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second and third trimester of pregnancy with
P. falciparum infection. Artesunate therapy in this
study reduced peripheral parasitaemia in pregnant
women. A single dose of oral artesunate is effective
and have no adverse effects on the second and
third trimester of pregnancy.8 A previous study has
found that anti-malaria artesunate monotherapy
in the second and third trimester of pregnancy has
a better efficacy compared to 6 doses of
artemetherlumefantrine.9 Artesunate may also
delay the onset of hemolysis in severe malaria.10
Artesunate is sodium salt of the hemisuccinate
ester of artemisinin. It is soluble in water but has
poor stability in aqueous solutions at neutral or
acid pH. It is rapidly absorbed with peak plasma
levels occuring after 1.5 hours for oral, rectal and
2 hours to 0.5 hours for injections.11 Artemisin and
its derivatives (artesunate, artemether, dihydro-
artemisinin) are rapidly hydrolyzed in vivo into the
activity dihidroartemisin with equivalent anti-
malaria.12 Four possible mechanisms of artemisin
action against plasmodia when artemisin activated
through disconnection intrinsic bond peroxide are
line error detoxify heme groups, the induction of
the alkylation process translational control of pro-
tein tumor (PfTCTP) and other proteins, inhibition
of PfATPase6 enzyme activity and interference the
function of Plasmodium mitochondria.13
In this study, we found that the parasites
remained in peripheral blood after being adminis-
tered with artesunate therapy in pregnant women
and in the placenta as well as umbilical cord of
newborns through RDT and microscopic examina-
tion. The prevalence of parasitaemia varied. This
might be a result of differences in the definition of
congenital malaria, maternal immunity level, types
of blood samples examined (peripheral blood or
cord blood of neonates), the expertise in micro-
scopic examination, the parasite detection methods
(microscopic or PCR) and differences in geographi-
cal factors of malaria-endemic areas.14 The preva-
lence of malarial parasite is different with different
examination methods. A previous study indicated
that the prevalence of malarial infection in the pla-
centa with RDT, microscopy and PCR was 95%,
70% and 100% while in the umbilical cord was
10%, 12.8% and 95%, respectively.15 Fetal
exposure to malarial parasites in utero has been
proposed to modify the immune response of
newborns, increasing their susceptibility to
symptomatic malaria infections at birth and
later in life.16-18
Low birth weight is one of the adverse outcomes
in pregnancy-associated malaria in all levels of
endemicity. Pregnant women with falciparum and
vivax malaria are at higher risk for low birth
weight. Low birth weight is associated with the
mechanical obstruction of malaria parasite that
attached to chondroitin sulphate A (CSA) receptors
in the syncytiotrophoblast of the placenta that
impaired circulation from mother to fetus and
affect the transport of oxygen and nutrients. But
research by Pongtasik conducted in malaria en-
demic areas of East Nusa Tenggara expression
CSA in pregnant women with placental malaria had
no correlation with malaria infection of peripheral
blood postpartum.19
Primigravida has been associated with increased
risk of malarial infection. In areas where P. falci-
parum is endemic, parity reduced vulnerability to
malaria infection during pregnancy. This is due to
lack of antibodies that can blocked adhesion of
erythrocytes-malaria infected to the placenta
CSA.20 CSA adhesion phenotype specific to placen-
tal parasites by the var gene expression (var2
csa).21 However, recent study suggested that CSA
expression in the placenta not associated with
parity and low birth weight.22
The majority of the newborns whose mothers
were administered with artesunate during preg-
nancy had normal weight. The risk of low birth
weight increased 2-fold in the area of stable trans-
mission if the mother suffered from placental ma-
laria with the largest effect on primigravidae. Odds
ratio (OR) of low birth weight 2-7 times higher in
primigravidae compared to multigravidae.1 The
median reduction in birthweight in the reviewed
studies was 150 g for P. falciparum or mixed infec-
tions and 108 g for P. vivax malaria. Malaria
reduces birthweight occurs mainly in first preg-
nancies with P. falciparum but also in subsequent
pregnancies, and even with one episode of P. vivax
or P. falciparum. Both symptomatic and asympto-
matic malaria episodes increase the risk of low
birth weight, although symptomatic infections in
pregnancy might have a larger effect than asymp-
tomatic disease, particularly on premature deli-
very.23
CONCLUSION
In brief, we found artesunate monotherapy could
reduce peripheral parasitaemia in the second and
third trimester of pregnancy in pregnant women
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with malarial infection. Newborns whose mothers
were received artesunate monotherapy had
normal weight.
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